Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RS_004
- Development stage
- Preclinical
- Lead developer
- Redesign Science
- Modality
- Small Molecules
01
Overview
RS_004 is a preclinical small molecule allosteric kinase inhibitor being developed by Redesign Science for the treatment of moderate to severe inflammatory bowel disease (IBD). Discovered using the company's proprietary NUVO™ technology platform, RS_004 is designed as a Targeted Protein Interaction Modulator (TPIM™). Unlike traditional orthosteric inhibitors that target the highly conserved ATP-binding pocket, RS_004 targets an allosteric site to modulate specific kinase-mediated protein-protein interactions. This mechanism is intended to provide enhanced selectivity and a differentiated therapeutic profile for chronic inflammatory conditions. The program is currently in the lead optimization phase.
Beyond the preview
Go deeper on RS_004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RS_004.